Transcutaneous immunization without heterologous adjuvant
AssigneeThe United States of America as represented by the Secretary of the Army
InventorsGregory M. Glenn, Carl R. Alving
Life of this patent
Estimating the term…
Loading patent…
AssigneeThe United States of America as represented by the Secretary of the Army
InventorsGregory M. Glenn, Carl R. Alving
Estimating the term…
Transcutaneous immunization can deliver antigen to the immune system through the stratum corneum without physical or chemical penetration to the dermis layer of the skin. This delivery system induces an antigen-specific immune response without the use of a heterologous adjuvant. This system can induce antigen-specific immune effectors after epicutaneous application of a formulation containing one or more antigensImmune responses that provide prophylactic and/or therapeutic treatments are preferred. Antigenic activities in the formulation may be found in the same molecule, two or more different molecules dissociated from each other, or multiple molecules in a complex formed by covalent or non-covalent bonds. For antigens which are proteinaceous, they may be provided in the formulation as a polynucleotide for transcutaneous genetic immunization. Besides simple application of a dry or liquid formulation to the skin, patches and other medical devices may be used to deliver antigen for immunization.
A method for inducing an antigen-specific immune response in a subject comprising:
Dependencies are inferred from the claim text.